bluebird bio Inc.’s (BLUE) gene therapy, Elivaldogene autotemcel, is scheduled to be reviewed by an FDA panel on June 10, 2022.Elivaldogene autotemcel, or Eli-cel in short, is developed for the treatment of cerebral adrenoleukodystrophy, a rare neurodegenerative disease primarily affecting young children that can lead to progressive, irreversible loss of neurologic function and death. Every year, around 40 persons in the United States are diagnosed with cerebral adrenoleukodystrophy. The FDA decision on eli-cel is expected on Sep.16, 2022.Eli-cel received regulatory approval in Europe last July and was launched under the brand name Skysona. However, the drug has been withdrawn from the European market due to pricing issues.BLUE closed Thursday’s (May 26, 2022) trading at $3.16.